Health

Molina Healthcare beat estimates and held guidance, yet its profit fell 53% and the stock sank about 5%

Adjusted EPS of $0.89 beat estimates and full-year guidance held, and after-hours sellers still took the Medicaid insurer down about 5%. The fight over whether Medicaid margins have turned moves to Thursday's 8 a.m. call.

Vincent JiangVincent Jiang · 3 min read
Share
Gail Boudreaux, chief executive of Elevance Health, in a dark green jacket against a white background
1 / 6Slide 1 of 6
Elevance chief executive Gail Boudreaux, who hours before Molina's report called Medicaid "moving from stabilization to improvement" as she raised Elevance's 2026 forecast.

Molina Healthcare−6.70% — Molina Healthcare, down 6.70 percent today reported third-quarter adjusted earnings of $0.89 a share on Wednesday, October 21, clearing the 72-cent average of analysts polled by Zacks, on revenue of $11.08 billion against $10.93 billion expected 2. It reaffirmed full-year guidance: roughly $42 billion of premium revenue and adjusted earnings of at least $5.25 a share 1. The stock still fell close to 5% in after-hours trading 34, after rising 6.3% in the month into the print, to above the average analyst price target of $209 6.

Half a cent on the dollar

The beat sits on a base that has collapsed. Adjusted earnings fell 53% from $1.84 a year earlier; GAAP net income fell 52% to $38 million 1. The medical care ratio, claims cost as a share of premium revenue, reached 92.9% overall and 93.0% in Medicaid, the largest segment 1. Adjusted pre-tax margin was 0.6% 1. At that margin, Molina has become a $42 billion toll road that keeps half a cent of every dollar, and one point of claims overrun erases the year 1.

Quarterly profit slid from about $300 million to a $160 million loss

-$200M$0M$200M$400MQ4 '23Q2 '24Q4 '24Q2 '25Q4 '25Break-even-$160MThe only loss in the series
Data
GAAP net income
Q3 '23$245M
Q4 '23$216M
Q1 '24$301M
Q2 '24$301M
Q3 '24$326M
Q4 '24$251M
Q1 '25$298M
Q2 '25$255M
Q3 '25$79M
Q4 '25-$160M
GAAP net income by quarter from Molina Healthcare's SEC filings via EDGAR, through Q4 2025, the latest quarter in the filing series. Molina reported net income of $38 million for Q3 2026 in Wednesday's earnings release, down 52% from a year earlier.10

Smaller on purpose

The fix management chose was shrinkage. Total membership ended September at 4.862 million, down from 5.628 million a year earlier 1, and revenue has now fallen year over year for three straight quarters 91.

Revenue has fallen year over year for three straight quarters

$8B$9B$10B$11B$12BQ3 '23Q1 '24Q3 '24Q1 '25Q3 '25Q1 '26Q3 '26$11.08B
Data
Total revenue
Q3 '23$8.55B
Q4 '23$9.05B
Q1 '24$9.93B
Q2 '24$9.88B
Q3 '24$10.34B
Q4 '24$10.5B
Q1 '25$11.15B
Q2 '25$11.43B
Q3 '25$11.48B
Q4 '25$11.38B
Q1 '26$10.8B
Q2 '26$10.87B
Q3 '26$11.08B
Total GAAP revenue by quarter. Q3 2023 to Q2 2026 from SEC filings via EDGAR; Q3 2026 from the October 21, 2026, earnings release.9,1

The retreat is concentrated in Marketplace, the Affordable Care Act exchange business: enrollment fell from 713,000 to 267,000, and segment premium revenue nearly halved to $642 million 1. The whole market is thinning after richer subsidies expired at the end of 2025; more than 4.6 million people had left the exchanges by June, and about a dozen carriers, Molina among them, are pulling out of states 5. Medicaid premium revenue still rose to $8.2 billion on state rate updates 1.

The shrink is a Marketplace story: segment premium revenue down 46%

  • Q3 2025
  • Q3 2026
$0M$5,000M$10,000MMedicaidMedicareMarketplace$1,197M
Data
Q3 2025Q3 2026
Medicaid$8,015M$8,199M
Medicare$1,610M$1,616M
Marketplace$1,197M$642M
Premium revenue by segment, Q3 2025 versus Q3 2026, company reported in the October 21, 2026, earnings release.1

Guidance already absorbs a $1.50-per-share loss from the new Florida Medicaid contract starting in the fourth quarter and $1.00 from exiting the Medicare Advantage prescription-drug book for 2027, while parent-company cash and investments were rebuilt to $608 million from $223 million at year-end 1.

The Medicaid turn finds a second witness

Chief Executive Joseph Zubretsky said medical cost trend appears to be plateauing and that Molina is "likely observing the beginning of the turn in Medicaid margins," pointing to 2027 rate updates 1. Hours earlier, Elevance−1.29% — Elevance, down 1.29 percent today, which covers 8.2 million Medicaid members, raised its 2026 forecast on stronger-than-expected July state rate increases, with Chief Executive Gail Boudreaux calling Medicaid "moving from stabilization to improvement" 7.

The bear reply is positioning and arithmetic: the beat cleared a bar set by a fourth-quarter 2025 loss 4, the rebound plan already targets $25 of earnings by 2029, and a October 14 Hold rating at $217 argued the recovery is priced in, with January's state rate letters the real test 8.

Thursday, 8 a.m.

The call opens at 8 a.m 1. Eastern on Thursday, October 22, with 2027 rates in hand 1. Listen for how much of the $5.25 already assumes that rate strength, and for whether Medicaid holds a 93% care ratio once Florida loads in 1. The next hard reading is January, when the 2027 rate letters land 8. Until then, both camps are trading the same word: turn.

Get Health by email, free

AI in medicine, pharma and biotech. In our daily email, every weekday.

Loading MOH…

Reader comments

0 comments

    More in Health

    All in this topic →

    Health

    Tempus AI tops 80% sensitivity on 12 lung biomarkers but withholds the specificity number

    An AI panel reading routine lung slides flagged all 12 NSCLC biomarkers above 80% sensitivity across 60,459 cases. The number Tempus withheld, specificity, decides whether the flag trims lab workload or sells more of its own tests, and it lands six days before the Q3 print.

    Health

    Intuitive cuts da Vinci revenue per procedure 3% to 5%, stock falls 8% to $405 despite a beat

    The robotic-surgery leader beat estimates on revenue and adjusted earnings, then told investors instrument revenue per procedure will fall 3% to 5% to buy volume. The stock dropped about 8% to near $405.

    Health

    Novo Nordisk's new 25% CagriSema figure counts only women who never quit; Zepbound's 25.5% stands

    Novo Nordisk republished CagriSema as a women's-health win on October 20: 25% average weight loss in a post-hoc subgroup, computed as if no patient quit treatment. The FDA decides this quarter on the file that lost the head-to-head to Zepbound.

    Health

    Eli Lilly hits a record high one week before the quarter that tests Ricks's volume bet

    Lilly reports Q3 on October 29, the first quarter containing the $50-copay Medicare Bridge, with the stock at a record high and guidance implying a sharp growth slowdown for the second half.

    Health

    Intuitive Surgical settles hospitals' da Vinci antitrust case for $450 million; the conduct terms are unread

    Intuitive settled the hospitals' da Vinci antitrust class action for $450 million plus injunctive relief nobody outside the deal has read. The cash is priced; the conduct terms are not, and they land on the instruments aftermarket the case was built around.

    Health

    Molina's earnings fix is shrinkage, and October 21 tests whether Medicaid can carry it

    Molina already made the quarter survivable by shrinking its worst book, exiting Ohio and California exchanges and trimming its 2027 premium revenue. The October 21 print only has to confirm whether Medicaid and duals can carry a business Molina is cutting down.

    Get the newsletter

    The day's AI and market news, in your inbox every weekday.